Breast Cancer
Agilent, Visiopharm Ink Distribution Agreement for AI-Based Digital Pathology Software
Agilent said the agreement marks its entry into digital pathology and expands the scope of a long-term collaboration with Danish firm Visiopharm.
Exact Sciences' Oncotype DX Breast Recurrence Score Assay Receives Japanese Regulatory Approval
The test helps guide treatment and provides risk of distant recurrence in patients with HR-positive, HER2-negative early-stage breast cancer.
The company is working with three institutions to recruit about 1,200 case-control participants for its validation study, with plans to launch an LDT next year.
Volpara Adding Invitae Genetic Test Ordering to Breast Risk Software Platform
The companies have inked an agreement under which Volpara can integrate Invitae's test services into its suite of risk assessment products.
Biocept HER2 Assay Gains Coverage Under Medicare Local Coverage Determination for CTC Tests
Under the LCD, CTC assays, such as Biocept's, will now be covered to guide targeted treatment decisions for patients with breast and other cancers under certain circumstances.